Coherus BioSciences (CHRS) Reports Q2 Loss of $1.56
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.37 +1.48%
EPS Growth %: +39.4%
Financial Fact:
Total operating expenses: 234.36M
Today's EPS Names:
ALZN, ASPU, OCCI, More
EPS Growth %: +39.4%
Financial Fact:
Total operating expenses: 234.36M
Today's EPS Names:
ALZN, ASPU, OCCI, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q2 EPS of ($1.56), versus ($5.90) reported last year. Revenue for the quarter came in at $6.87 million, versus $4.46 million reported last year.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Raymond James Reiterates Underperform Rating on Lennar (LEN)
- Bernstein SocGen Group Upgrades Engie SA (ENGI:FP) (ENGIY) to Outperform
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
